title: Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features.
abstract: Secretin, a gastrointestinal (GI) peptide, may offer therapeutic benefit in autism. Autistic features can also be present in schizophrenia and a recent study suggested a role for adjunctive secretin in treatment-resistant schizophrenia. The current report describes one patient with undifferentiated schizophrenia and prominent autistic features who received a single dose of secretin and demonstrated substantial yet transient improvement. The case illustrates the potential role of secretin as a novel adjunctive treatment strategy in schizophrenic patients with autistic features.
authors.affiliation: Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7160, USA.
authors.forename: Sayed S
authors.initials: SS
authors.lastname: Alamy
authors.forename: L Fredrik
authors.initials: LF
authors.lastname: Jarskog
authors.forename: Brian B
authors.initials: BB
authors.lastname: Sheitman
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001321:Autistic Disorder / Q000150:complications*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012633:Secretin / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D012633:Secretin